[1]储玉山,朱小庆,张玉宇,等.索拉非尼联合奥沙利铂对肝癌ＨｅｐＧ２细胞的抑制作用[J].介入放射学杂志,2011,(10):810.
　CHU Yu-shan,ZHU Xiao-qing,ZHANG Yu-yu,et al. The inhibitory effect of sorafenib together with oxaliplatin on the growth of human hepatic carcinoma cell line HepG2 in vitro[J].J Intervent Med,2011,(10):810.
点击复制

索拉非尼联合奥沙利铂对肝癌ＨｅｐＧ２细胞的抑制作用()

PDF下载中关闭

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2011年10期
页码:
810
栏目:
实验研究
出版日期:
2011-10-25

文章信息/Info

Title:

The inhibitory effect of sorafenib together with oxaliplatin on the growth of human hepatic carcinoma cell line HepG2 in vitro

作者:
储玉山;  朱小庆;  张玉宇;  陆小华;  曹建民
江苏省南通大学附属医院介入放射科
Author(s):

CHU Yu-shan;  ZHU Xiao-qing;  ZHANG Yu-yu;  LU Xiao-hua;  CAO Jian-min.
Department of Interventional Radiology, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province 226001, China
关键词:
肝癌; 　索拉非尼; 　奥沙利铂; 　联合用药; 　协同作用
分类号:
Ｒ７３５.７
文献标志码:
A
摘要:
目的 　　探讨索拉非尼联合奥沙利铂（ＬＯＨＰ）对肝癌细胞ＨｅｐＧ２的抑制作用及其可能的分子机制。方法 索拉非尼和ＬＯＨＰ单独及联合给药后以ＣＣＫ８法测定ＨｅｐＧ２细胞的增殖，用流式细胞仪检测细胞周期及凋亡，用Ｗｅｓｔｅｒｎ ｂｌｏｔ观察ＥＲＫ及ｐＥＲＫ蛋白的表达。结果 索拉非尼及ＬＯＨＰ单药对ＨｅｐＧ２均有抑制作用，两药联合具有协同或相加作用（Ｐ ＜ ０．０５）。索拉非尼及ＬＯＨＰ分别主要使细胞阻滞于Ｇ１及Ｓ期。两药联用后同时阻滞于Ｇ１及Ｓ期。联合组细胞凋亡率明显比各单药组高（Ｐ ＜ ０．０５）。单用及联合用药对ＨｅｐＧ２细胞ＥＲＫ表达无明显影响，索拉非尼及联合用药减少ｐＥＲＫ的表达。结论 索拉非尼和ＬＯＨＰ对肝癌ＨｅｐＧ２细胞有增殖抑制及促凋亡作用，两药联合表现为协同或相加作用，其机制可能与细胞周期的双重阻滞及细胞增殖通路Ｒａｆ／ＭＥＫ／ＥＲＫ的抑制有关。

参考文献/References:

[1] Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359: 378 - 390.
[2] Villanueva A, Newell P, Chiang DY, et al. Genomics and signaling pathways in hepatocellular carcinoma[J]. Semin Liver Dis, 2007, 27: 55 - 76.
[3] Beeram M, Patnaik A, Rowinsky EK. Regulation of c-Raf-1: therapeutic implications[J]. Clin Adv Hematol Oncol, 2003, 1: 476 - 481.
[4] Tannapfel A, Sommerer F, Benicke M, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma[J]. Gut, 2003, 52: 706 - 712.
[5] Hwang YH, Choi JY, Kim S, et al. Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma[J]. Hepatol Res, 2004, 29: 113 - 121.
[6] Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J]. Cancer Res, 2004, 64: 7099 - 7109.
[7] Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models[J]. Cancer Chemother Pharmacol, 2007, 59: 561 - 574.
[8] Cheng AL, Kang Y, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-biind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10: 25 - 34.
[9] Lian M, Liu Y, Yu SZ, et al. Hepatitis B virus x gene and cyanobacterial toxins promote aflatoxin B1-induced hepatotumor-igenesis in mice[J]. World J Gastroenterol, 2006, 12: 3065 - 3072.
[10] Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J]. Cancer Res, 2006, 66: 11851 - 11858.
[11] Lee S, Yoon S, Kim DH. A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian Cancer cells[J]. Gynecol Oncol, 2007, 104: 338 - 344.
[12] Katayama K, Yoshioka S, Tsukahara S, et al. Inhibition of the mitogen-activated protein kinase pathway results in the down-regnlation of P-glycoprotein[J]. Mol Cancer Ther, 2007, 6: 2092 - 2102.
[13] 丁晓蕾, 张 阳, 吴 涛. 索拉非尼逆转肝癌细胞株HepG2/GEM耐药作用的实验研究[J]. 中华肿瘤防治杂志, 2010, 17: 1160 - 1163.
[14] 闫 东, 刘德忠, 曾辉英, 等. TACE联合索拉非尼治疗肝细胞癌的临床观察[J]. 临床肿瘤学杂志, 2010, 15: 359 - 361.
[15] 黄 振, 毕新宇, 赵建军, 等. 索拉非尼联合经导管肝动脉化疗栓塞治疗无远处转移的晚期肝细胞癌[J]. 临床肿瘤学杂志, 2010, 15: 355 - 358.



 

相似文献/References:

[1]董永华,林贵.肝癌介入治疗对靶血管损害的影像学评价及预防[J].介入放射学杂志,1992,(01):17.
[2]陶正龙,程永德,钱锡桂,等.肝癌碘油栓塞后肝区平片所见碘油沉积量与疗效关系[J].介入放射学杂志,1993,(01):19.
[3]王颂章,曹钦昊,魏崇健,等.肝癌动门脉短路的X线诊断与介入治疗[J].介入放射学杂志,1993,(01):9.
[4]颜志平,周康荣.碘油完全充填肝癌病灶的CT与肝动脉造影比较研究[J].介入放射学杂志,1994,(02):72.
[5]倪鎏达,陈成伟,茹素娟,等.中晚期肝癌化学免疫治疗与单纯TAE治疗疗效比较[J].介入放射学杂志,1994,(02):82.
[6]欧阳墉,马和平,张学军,等.肝癌经导管脉灌注栓塞中操作技术对疗效的影响[J].介入放射学杂志,1995,(01):9.
[7]陈雪萍,程永德.肝癌肝动脉化疗栓塞术后影响甲胎蛋白下降因素探讨[J].介入放射学杂志,1995,(02):73.
[8]刘平,曾伟华,李后炳,等.肝癌介入治疗药动学及其临床意义探讨[J].介入放射学杂志,1995,(02):67.
[9]戴定可,翟仁友,于平,等.肝动脉化疗、栓塞与肝静脉暂时闭塞治疗肝癌[J].介入放射学杂志,1996,(01):17.
[10]贾雨辰,刘崎,贺佳,等.COX模型对肝癌预后因素的分析[J].介入放射学杂志,1996,(01):7.

备注/Memo

备注/Memo:
收稿日期：２０１１０６０４
更新日期/Last Update: 2011-10-25